Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

  • There is currently no data for BMK

Directorate Change

29 Nov 2023 07:01

RNS Number : 9803U
Benchmark Holdings PLC
29 November 2023
Β 

29 November 2023

Β 

Benchmark Holdings plc

("Benchmark" or the "Company")

Directorate Change

The Company is pleased to announce the appointment ofΒ Jonathan EsfandiΒ as Non-Executive Director.Β Mr Esfandi is the founder and managing partner at JNE Partners LLP.Β 

Mr. EsfandiΒ will act as shareholder representative of JNE Partners LLP, a significant shareholder of the Company, and therefore the Board has concluded that he is not an independent director.Β 

Laura Lavers, who joined the Board in November 2022, will retire from the Board as a Non-Executive Director with effect from today.

Β 

Peter George, Chairman, commented:

"We welcome Jonathan to the Board and look forward to working together. On behalf of the Board, I wish to thankΒ Laura Lavers for her contribution over the past year."

The following information is disclosed in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies in connection with the appointment of Jonathan to the Board of the Company:

FullΒ Name:Β Jonathan Esfandi

Age: 49

Current Directorships:Β 

JNE PARTNERS LLP

JNE PARTNERS (UK) SERVICES LTD

Former Directorships (previous five years): None within the past five years

Beneficial interest in the equity securities ofΒ Benchmark Holdings plc: No direct beneficial interest. Funds managed by JNE Partners LLP have a holding of 169,263,811 shares in Benchmark

There is no further information required to be disclosed under Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Β 

Enquiries

For further information, please contact:

Benchmark Holdings plc

Tel: 0114 240 9939

Trond Williksen, CEO

Septima Maguire, CFO

Ivonne Cantu, Investor Relations

Deutsche Numis (Nominated Adviser and Broker)

Tel: 020 7260 1000

Freddie Barnfield,Β Duncan Monteith,Β Sher Shah

MHP

Tel: 020 3128 8004

Katie Hunt,Β Reg Hoare

benchmark@mhpgroup.com

Β 

Equity Development

Hannah Crowe

Β 

Tel: 020 7065 2692

Β 

About Benchmark

Benchmark is a leading aquaculture biotechnology company. Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology to develop innovative products and solutions which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), specialist diets and probiotics and sea lice treatments. Find out more atΒ www.benchmarkplc.com.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
BOADXBDBXGDDGXI
Date   Source Headline
3rd Apr 20174:32 pmRNSBlock Listing Six Monthly Return
9th Mar 20178:44 amRNSDirector Share Options and Issue of Shares
7th Mar 201710:39 amRNSResult of AGM
7th Mar 20178:00 amRNSContract Win
2nd Mar 20173:34 pmRNSHolding(s) in Company
1st Mar 20172:09 pmRNSHolding(s) in Company
23rd Feb 20177:00 amRNSHolding(s) in Company
22nd Feb 20174:35 pmRNSHolding(s) in Company
16th Feb 20177:45 amRNSDirector Dealings
24th Jan 20177:00 amRNSFinal Results
3rd Jan 20177:00 amRNSTotal Voting Rights
1st Dec 20167:00 amRNSDirector/PDMR Shareholding
29th Nov 20167:00 amRNSCapital Markets Day
25th Nov 20167:00 amRNSAppointment of Non-Executive Director
23rd Nov 20164:52 pmRNSHolding(s) in Company
26th Oct 20167:00 amRNSTrading Statement
12th Oct 20167:00 amRNSBlock Admission Application
10th Oct 201612:02 pmRNSBlock listing Interim Review
31st Aug 20167:00 amRNSBenchmark secures innovative new equine vaccine
12th Aug 201612:41 pmRNSHolding(s) in Company
11th Aug 20167:00 amRNSAcq of South American shrimp breeding programme
10th Aug 20163:37 pmRNSHolding(s) in Company
10th Aug 20161:40 pmRNSHolding(s) in Company
10th Aug 20161:33 pmRNSHolding(s) in Company
10th Aug 20161:29 pmRNSHolding(s) in Company
9th Aug 20163:26 pmRNSHolding(s) in Company
5th Aug 20167:00 amRNSPlacing of 47.3 million new ordinary shares
29th Jul 20167:00 amRNSDirectorate Change
19th Jul 20167:00 amRNSNew Seabass Vaccine Commences Field Trials
12th Jul 20167:00 amRNSBreeding & Genetics Contract Win
28th Jun 20167:00 amRNSHalf-year Report
3rd Jun 20167:00 amRNSChange of Adviser
27th May 20167:00 amRNSChange of Auditor
26th May 20167:00 amRNSTrading Update and Notice of Results
22nd Apr 201610:45 amRNSHolding(s) in Company
18th Apr 20169:40 amRNSIssue of Equity
22nd Mar 20169:07 amRNSBlocklisting Interim Review
10th Mar 201610:13 amRNSResult of AGM
5th Feb 20162:51 pmRNSDirector Dealings
2nd Feb 20167:00 amRNSFinal Results
7th Jan 201611:02 amRNSHolding(s) in Company
5th Jan 201612:08 pmRNSHolding(s) in Company
4th Jan 20163:04 pmRNSHolding(s) in Company
4th Jan 20163:00 pmRNSHolding(s) in Company
4th Jan 201611:18 amRNSHolding(s) in Company
4th Jan 201610:47 amRNSHolding(s) in Company
4th Jan 201610:43 amRNSHolding(s) in Company
4th Jan 201610:40 amRNSHolding(s) in Company
4th Jan 20169:26 amRNSHolding(s) in Company
4th Jan 20169:19 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.